KPRX vs ARBB Comparison

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

ARB IOT Group Ltd is a provider of complete solutions to the clients for the integration of Internet of Things (IoT) systems and devices from designing to project deployment. The company offers a wide range of IoT systems as well as provides customers with a substantial range of services such as system integration and system support services. It delivers solutions like designing, installation, testing and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company operates in two reportable segments: (i) the provision of hardware and software of IoT solutions and (ii) Investment holding and others. The majority of revenue is generated from the IoT solutions segment.